Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial

[1]  H. Iwata,et al.  Abstract S1-07: A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04) , 2016 .

[2]  H. Cohen,et al.  Standard chemotherapy versus capcitabine for older women with early stage breast cancer: An update of CALGB/CTSU/Alliance 49907. , 2015 .

[3]  S. Barni,et al.  Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial , 2015, The Lancet.

[4]  Amy P Abernethy,et al.  Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). , 2014, Journal of the National Cancer Institute.

[5]  P. Bruzzi,et al.  Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. , 2014, Cancer treatment reviews.

[6]  A. Sasse,et al.  Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis. , 2012 .

[7]  E. Basch,et al.  Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. , 2011, Journal of the National Cancer Institute.

[8]  Val Gebski,et al.  Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Andreas Schneeweiss,et al.  Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Perez,et al.  Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. , 2010, The New England journal of medicine.

[11]  M. Rezai,et al.  Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Ethan Basch,et al.  The missing voice of patients in drug-safety reporting. , 2010, The New England journal of medicine.

[13]  I. Ellis,et al.  Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial , 2009, The Lancet.

[14]  Arrate Plazaola,et al.  Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. , 2008, Journal of the National Cancer Institute.

[15]  E. Perez,et al.  Weekly paclitaxel in the adjuvant treatment of breast cancer. , 2008, The New England journal of medicine.

[16]  Lyndsay Harris,et al.  Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Cameron,et al.  Anglo-Celtic IV: First results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC) , 2007 .

[18]  H. Earl,et al.  Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. , 2006, The New England journal of medicine.

[19]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[20]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[22]  Huston Gj,et al.  The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.

[23]  V. Kataja,et al.  Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Cutter,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials , 2012, The Lancet.

[25]  J. Thigpen.  Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer , 2009 .

[26]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[27]  D. Osoba,et al.  Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.